Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug Screening

8 Feb 2024

Abstract excerpt

Triple-negative breast cancer (TNBC) poses a therapeutic challenge due to its aggressive nature and lack of targeted therapies. Epigenetic modifications contribute to TNBC tumorigenesis and drug resistance, offering potential therapeutic targets. Recent advancements in three-dimensional (3D) organoid cultures, enabling precise drug screening, hold immense promise for identifying novel compounds targeting TNBC. In...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Cells and Metastasis
Share to Epigenetics and DNA Methylation
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38399440
DOI: 10.3390/ph17020225

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Unveiling Epigenetic Vulnerabilities in Triple-Negative Breast Cancer through 3D Organoid Drug ScreeningPMID 38399440Read ↗

Patient-derived triple negative breast cancer organoids provide robust model systems that recapitulate tumor intrinsic characteristicsSemantic proximity Read ↗

Breast Cancer Organoids Model Patient-Specific Response to Drug TreatmentSemantic proximity Read ↗

Targeting cancer drug resistance utilizing organoid technologySemantic proximity Read ↗

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.Semantic proximity Read ↗

Epigenetics of Triple-Negative Breast Cancer via Natural CompoundsSemantic proximity Read ↗

Organoid-evaluable clinical biomarkers predict drug responses and guide new breast cancer therapiesSemantic proximity Read ↗

Evaluating Drug Response in 3D Triple Negative Breast Cancer Tumoroids with High Content Imaging and AnalysisSemantic proximity Read ↗

Epi-drugs as triple-negative breast cancer treatmentSemantic proximity Read ↗

Hi-C profiling of cancer spheroids identifies 3D-growth-specific chromatin interactions in breast cancer endocrine resistanceSemantic proximity Read ↗

Mitotic kinases are emerging therapeutic targets against metastatic breast cancerSemantic proximity Read ↗

Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous diseaseSemantic proximity Read ↗

Single‐cell transcriptional atlas of human breast cancers and model systemsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.